Phentermine vs GLP-1 Agonists: UK Weight Loss Comparison
By Dr David Chen, PharmD · Reviewed by the Editorial Board
Old generation vs new: how does phentermine compare with GLP-1 agonists for weight loss in the UK? This guide covers efficacy, safety, cost, and access.
Table of Contents (5 sections)
Two Generations of Weight Loss Medication
Phentermine and GLP-1 agonists represent fundamentally different approaches to pharmacological weight management — separated by decades of neuroscience and metabolic understanding.
Phentermine (1959): - Sympathomimetic amine (amphetamine analogue) - Works by increasing noradrenaline release in the hypothalamus - Reduces appetite through CNS stimulation - Approved for short-term use only (up to 12 weeks)
GLP-1 agonists (2014-present): - Incretin hormone analogues - Work through multiple physiological pathways (appetite, gastric emptying, satiety) - Approved for long-term/chronic use - Semaglutide (Wegovy), tirzepatide (Mounjaro), liraglutide (Saxenda)
The shift from phentermine to GLP-1 agonists represents a paradigm change — from crude appetite suppression to sophisticated metabolic modulation.
Efficacy: How Much Weight Do You Lose?
Phentermine: - Average weight loss: 3-5% body weight over 12 weeks - Limited long-term data (not approved for >12 weeks) - Weight regain is common after discontinuation - Modest efficacy by modern standards
GLP-1 agonists: - Semaglutide 2.4mg (Wegovy): 15-17% body weight loss over 68 weeks (STEP 1) - Tirzepatide (Mounjaro): 20-26% body weight loss over 72 weeks (SURMOUNT-1) - Liraglutide 3mg (Saxenda): 5-10% body weight loss over 56 weeks (SCALE) - Long-term data available (2+ years for semaglutide)
GLP-1 agonists are 3-5 times more effective than phentermine for weight loss, with the gap widening at longer treatment durations.
UK Availability and Prescribing
Phentermine in the UK: - Classified as a controlled substance (Class C; Schedule 3 of the Misuse of Drugs Regulations 2001) - Very rarely prescribed — most UK GPs will not prescribe it - Not recommended by NICE for obesity management - Some private clinics offer it, but this is uncommon - Short-term licence only (max 12 weeks) - Not available on the NHS for weight management
GLP-1 agonists in the UK: - Wegovy (semaglutide 2.4mg): NICE-approved (TA875), available on NHS with criteria (BMI ≥30, or ≥27 with comorbidities), available privately - Mounjaro (tirzepatide): NICE-approved (TA924), available on NHS and privately - Saxenda (liraglutide 3mg): NICE-approved (TA664), available on NHS and privately - All available through private online pharmacies and clinics
The clear message: GLP-1 agonists are the standard of care for pharmacological weight management in the UK. Phentermine has largely been superseded.
Safety Comparison
Phentermine side effects: - Cardiovascular: Increased heart rate, elevated blood pressure, palpitations - CNS: Insomnia, restlessness, anxiety, tremor - Dependency potential: Classified as a controlled substance due to amphetamine-like properties - Contraindications: Cardiovascular disease, hypertension, hyperthyroidism, history of substance abuse, concurrent MAOIs
GLP-1 agonist side effects: - Gastrointestinal: Nausea, vomiting, diarrhoea, constipation (most common, typically improves) - Pancreatitis: Rare but serious - Gallbladder: Increased risk during rapid weight loss - Cardiovascular: Generally POSITIVE — semaglutide reduced MACE by 20% (SELECT trial) - No dependency potential
Key safety difference: Phentermine increases cardiovascular risk. GLP-1 agonists reduce it. This is the single most important distinction for clinical decision-making, particularly in obese patients who already have elevated cardiovascular risk.
Cost Comparison (UK)
Phentermine (if available privately): - ~£30-60/month for medication - Plus consultation fees (£100-200) - Maximum 12-week treatment courses - Total typical cost: £200-400 per course
GLP-1 agonists: - NHS: Standard prescription charge (£9.90/item in England, free in Scotland/Wales/NI) - Wegovy privately: £200-300/month - Mounjaro privately: £150-250/month - Saxenda privately: £150-200/month - Plus initial consultation (£100-250) and monitoring - Ongoing treatment — costs continue monthly
Phentermine is cheaper per course but less effective. GLP-1 agonists are more expensive monthly but dramatically more effective and available on the NHS.
*This comparison is for educational purposes only. Weight management medication should only be used under medical supervision. Consult your GP or a specialist for personalised advice.*
Related Peptide Profiles
Related Research Guides
Related Comparisons
Related Articles
Peptide Therapy Cost UK 2026: Complete Pricing Breakdown
A detailed cost breakdown for every peptide therapy route in the UK — from NHS prescriptions at £9.90 to private clinic fees and research peptide supplier pricing.
9 min readHow to Get Ozempic Privately in the UK
Ozempic is available privately in the UK for those who meet eligibility criteria. This guide covers private GP routes, online pharmacies, telehealth consultations, costs ranging from £150–300 per month, and what you need to know before seeking a private prescription.
9 min readPrivate GLP-1 Prescriptions UK: Cost Comparison Guide
GLP-1 receptor agonists are available privately in the UK, but costs vary significantly between medications and providers. This guide provides a detailed cost comparison of Wegovy, Mounjaro, and Saxenda through private routes, plus consultation fees and ongoing monitoring costs.
10 min readSaxenda vs Wegovy vs Mounjaro: UK Weight Loss Comparison
Saxenda, Wegovy, and Mounjaro represent three generations of injectable weight loss treatment available in the UK. This guide compares their mechanisms, clinical trial results, dosing schedules, NHS eligibility criteria, and private costs to help you make an informed choice.
10 min read